Advanced Solid Tumors
Conditions
Keywords
Drug Therapy
Brief summary
The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of Niraparib in Japanese participants with advanced solid tumors.
Detailed description
The drug being tested in this study is called Niraparib. Niraparib is being tested to treat Japanese participants with advanced solid tumors. This study will look at the safety, tolerability and pharmacokinetics of Niraparib administered once daily orally. The study will enroll approximately 12 participants as a maximum. Participants will be assigned to Cohort 1 (21-day treatment cycle). After that, participants will be assigned to Cohort 2 when safety and tolerability of the 200 mg dose will be demonstrated. This single-center trial will be conducted in Japan. The overall time to participate in this study is approximately 16 months. Participants will make multiple visits to the clinic with final visit approximately 28 days after last dose of study drug for a follow-up assessment.
Interventions
DRUGNiraparib
Niraparib capsule
Sponsors
Takeda
Study design
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
OTHER
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
20 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Japanese male or female participants aged 20 years or older on the day of signing informed consent. 2. Participants must have a cytologically- or histologically-confirmed metastatic or locally advanced solid tumor and have failed or progressed after standard therapy, or for which standard therapy does not exist in the opinion of the investigator. 3. Participants must have Performance Status of less than or equal to (\<=) 1 on the Eastern Cooperative Oncology Group (ECOG) Performance Status Scale. 4. Participants must have adequate organ function as indicated by the following laboratory values: 1. Hematology * Absolute neutrophil count: greater than or equal to (\>=) 1500 per microliter (μL) * Platelet count: \>=100,000/μL * Hemoglobin: \>=9 gram per deciliter (g/dL) 2. Kidney \- Serum creatinine: \<=1.5\*institutional upper limit of normal (ULN), OR creatinine clearance of \>=50 milliliter per minute (mL/min) (as calculated using the Cockcroft Gault equation or measured using 24-hour urine creatinine clearance) for participants with creatinine levels \>=1.5\*institutional ULN. 3. Liver * Total bilirubin in serum: \<=1.5\*ULN (except in participants with Gilbert's syndrome). Participants with Gilbert's syndrome may be enrolled if the participant's direct bilirubin is \<=1.5\*ULN of the direct bilirubin. * Aspartate aminotransferase (AST) and alanine aminotransferase (ALT): \<=2.5\*ULN OR \<=5\*ULN if participants have liver metastases. 4. Coagulation (does not pertain to participants receiving anticoagulants) * Prothrombin time (PT): \<=1.2\*ULN * Activated partial thromboplastin time (aPTT): \<=1.2\*ULN 5. Female participants who: * Are postmenopausal for at least 1 year before the screening visit, OR * Are surgically sterile, OR * If they are of childbearing potential, agree to practice one highly effective method of contraception and one additional effective (barrier) method at the same time, from the time of signing the informed consent through 180 days after the last dose of study drug, OR * Agree to practice true abstinence, when this is in line with the preferred and usual lifestyle of the participant. (Periodic abstinence \[eg, calendar, ovulation, symptothermal, postovulation methods\], condoms only, withdrawal, spermicides only, and lactational amenorrhea are not acceptable methods of contraception. Female and male condoms should not be used together.) Male participants, even if surgically sterilized (ie, vasectomy), who: * Agree to practice effective barrier contraception during the entire study treatment period and through 120 days after the last dose of study drug. If the female partner of a male participant is of child bearing potential, it should also be advised to use a highly effective method of contraception, OR * Agree to practice true abstinence, when this is in line with the preferred and usual lifestyle of the participant. (Periodic abstinence \[eg, calendar, ovulation, symptothermal, postovulation methods for the female partner\], condoms only, withdrawal, spermicides only, and lactational amenorrhea are not acceptable methods of contraception. Female and male condoms should not be used together.) 6. Voluntary written consent must be given before performance of any study related procedure not part of standard medical care, with the understanding that consent may be withdrawn by the participant at any time without prejudice to future medical care.
Exclusion criteria
1. Participant who have received chemotherapy, radiotherapy, hormonal or biological therapy within 14 days (within 28 days for anticancer monoclonal antibody, within 42 days for nitrosoureas or mitomycin C) prior to Cycle 1 Day 1. If the participant has residual toxicity from prior chemotherapy treatment, such toxicity must be \<=Grade 1 (NOTE: participants with Grade 2 alopecia may qualify for this study). If bevacizumab had been used in the past, all bevacizumab-related toxicities must have resolved. Participants with prostate cancer may have been treated with luteinizing hormone-releasing hormone (LH-RH) analogs. 2. Participants who received a known or putative poly (ADP-ribose) polymerase (PARP) inhibitor or other drugs that may inhibit the PARP, either as part of a clinical trial or as standard of care. 3. Participants who initiated bisphosphonate therapy or are adjusting bisphosphonate dose/regimen within 30 days prior to Cycle 1 Day 1. Participants on a stable bisphosphonate regimen are eligible and may continue the treatment. 4. Treatment with any investigational products within 28 days or 5 half-lives (whichever was longer) before Cycle 1 Day 1. 5. Participants who have symptomatic ascites or a symptomatic pleural effusion. A participant who is treated and clinically stable for these conditions is eligible. 6. Participants with a known primary central nervous system (CNS) tumor. 7. Participants with known CNS metastases and/or carcinomatous meningitis are excluded. However, participants with CNS metastases who have completed a course of therapy would be eligible for the study provided they are clinically stable for 30 days prior to Cycle 1 Day 1 defined as: (1) no evidence of new or enlarging CNS metastases, (2) off steroids, or (3) on a stable dose and administration of steroids. 8. Participants who have a hypersensitivity to the components of the study drugs or their analogs. 9. Participants who are considered to be at high medical risk due to a serious, uncontrolled disease, non-malignant systemic disease or active, uncontrolled infection. Examples include, but are not limited to, uncontrolled ventricular arrhythmia, recent (within 90 days prior to Cycle 1 Day 1) myocardial infarction, uncontrolled major seizure disorder, unstable spinal cord compression, superior vena cava syndrome, uncontrolled hypertension, or any psychiatric disorder that prohibits obtaining informed consent. 10. Participants who have a history or current evidence of any condition, therapy, or lab abnormality that might confound the results of the study, interfere with the participant's participation throughout the study period, or study participation is not in the best interest of the participant. 11. Known gastrointestinal (GI) disease or GI surgery that could interfere with the GI absorption of study drug, such as difficulty swallowing capsules and total gastrectomy. 12. Participants who have a psychiatric disorder that may interfere with the conduct of the trial. 13. Participant is, at the time of signing informed consent, a regular user (including recreational use) of any illicit drugs or had a recent history (within the past year) of drug or alcohol abuse. 14. Participants who are pregnant or breast-feeding, or expecting to conceive or be a father of children within the planned duration of the study. NOTE: If a breast-feeding woman discontinue breast-feeding, she may be enrolled in the study. 15. Known human immunodeficiency virus positive. 16. Known hepatitis B surface antigen (HBsAg) positive, or known or suspected active hepatitis C virus (HCV) infection. NOTE: Participants who are positive for hepatitis B core antibody (HBcAb) or hepatitis B surface antibody (HBsAb) can be enrolled but must have an undetectable hepatitis B virus (HBV) viral load. Participants who have positive hepatitis C virus antibody (HCVAb) must have an undetectable HCV viral load.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants Who Discontinued Study Drug Due to TEAEs | From the first dose of the study drug up to 28 days after the last dose of the study drug (up to Cycle 22 Day 49) (Cycle length =21 days) | — |
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) | From the first dose of the study drug up to 28 days after the last dose of the study drug (up to Cycle 22 Day 49) (Cycle length =21 days) | — |
| Number of Participants With Grade 3 or Higher TEAEs | From the first dose of the study drug up to 28 days after the last dose of the study drug (up to Cycle 22 Day 49) (Cycle length =21 days) | TEAEs were graded as per the NCI-CTCAE version 4.03. As per the NCI-CTCAE, Grade 1 (mild, asymptomatic or mild symptoms); Grade 2 (moderate, minimal, local or noninvasive intervention indicated); Grade 3 (severe or medically significant but not immediately life-threatening, hospitalization or prolongation of hospitalization indicated); Grade 4 (life-threatening consequences, urgent intervention indicated); Grade 5 (death related to adverse event \[AE\]). |
| Number of Participants With Serious TEAEs | From the first dose of the study drug up to 28 days after the last dose of the study drug (up to Cycle 22 Day 49) (Cycle length =21 days) | — |
| Number of Participants With Dose Limiting Toxicities (DLTs) | Baseline up to Day 21 in Cycle 1 (Cycle length=21 days) | DLT was evaluated as per National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), v4.03 and defined as any of the following events occurring during Cycle 1 that were considered by investigator to be related with niraparib: Any Grade 5 or 4 hematologic toxicity, except Grade 4 neutropenia less than (\<) 7 days; Grade 3 or 4 neutropenia with fever greater than (\>) 38.5 degree Celsius and/or infection requiring antibiotic/anti-fungal treatment; Any Grade 3, 4,or 5 non-hematologic toxicity except: Grade 3 nausea, vomiting, diarrhea/dehydration occurring in setting of inadequate compliance with supportive care and lasting \<48 hours, Inadequately treated hypersensitivity reactions, Grade 3 acidosis/alkalosis that responded to intervention by improving to less than or equal to (\<=) Grade 2 within 48 hours, Isolated asymptomatic Grade 3 amylase elevation, hypercholesterolemia and hypertriglyceridemia; Any TEAE leading to an interruption of niraparib for \>14 days. |
Secondary
| Measure | Time frame |
|---|---|
| Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for Niraparib | Cycle 1 Days 1 and 21: pre-dose and at multiple time points (up to 24 hours) post-dose (Cycle length =21 days) |
| AUC24：Area Under the Plasma Concentration-time Curve From Time 0 to 24 Hours for Niraparib | Cycle 1 Days 1 and 21: pre-dose and at multiple time points (up to 24 hours) post-dose (Cycle length =21 days) |
| Cmax: Maximum Observed Plasma Concentration for Niraparib | Cycle 1 Days 1 and 21: pre-dose and at multiple time points (up to 24 hours) post-dose (Cycle length =21 days) |
Countries
Japan
Participant flow
Recruitment details
Participants took part in the study at 1 investigative site in Japan from 5 April 2018 to 10 February 2020.
Pre-assignment details
Japanese participants with advanced solid tumors were enrolled in this dose-escalation study to receive niraparib 200 milligram (mg) in Cohort 1 and niraparib 300 mg in Cohort 2.
Participants by arm
| Arm | Count |
|---|---|
| Cohort 1: Niraparib 200 mg Niraparib 200 mg, capsule, orally, once daily, in each 21-day treatment cycle until objective disease progression, unacceptable toxicity or until study discontinuation due to any other reasons. | 3 |
| Cohort 2: Niraparib 300 mg Niraparib 300 mg, capsule, orally, once daily, in each 21-day treatment cycle until objective disease progression, unacceptable toxicity or until study discontinuation due to any other reasons. | 6 |
| Total | 9 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Overall Study | Adverse Event | 0 | 2 |
| Overall Study | Progressive disease | 3 | 4 |
Baseline characteristics
| Characteristic | Cohort 1: Niraparib 200 mg | Cohort 2: Niraparib 300 mg | Total |
|---|---|---|---|
| Age, Continuous | 53.0 years STANDARD_DEVIATION 13.75 | 61.3 years STANDARD_DEVIATION 12.99 | 58.6 years STANDARD_DEVIATION 13.04 |
| Body Mass Index (BMI) | 23.56 kilogram per square meter (kg/m^2) STANDARD_DEVIATION 2.614 | 23.89 kilogram per square meter (kg/m^2) STANDARD_DEVIATION 1.887 | 23.78 kilogram per square meter (kg/m^2) STANDARD_DEVIATION 1.99 |
| Breast Cancer Susceptibility Gene 1 (BRCA1) Mutant Did not have BRCA1 mutant | 1 Participants | 1 Participants | 2 Participants |
| Breast Cancer Susceptibility Gene 1 (BRCA1) Mutant Had BRCA1 mutant | 0 Participants | 0 Participants | 0 Participants |
| Breast Cancer Susceptibility Gene 1 (BRCA1) Mutant Unknown | 2 Participants | 5 Participants | 7 Participants |
| Breast Cancer Susceptibility Gene 2 (BRCA2) Mutant Did not have BRCA2 mutant | 0 Participants | 0 Participants | 0 Participants |
| Breast Cancer Susceptibility Gene 2 (BRCA2) Mutant Had BRCA2 mutant | 1 Participants | 1 Participants | 2 Participants |
| Breast Cancer Susceptibility Gene 2 (BRCA2) Mutant Unknown | 2 Participants | 5 Participants | 7 Participants |
| Diagnosis Other | 2 Participants | 5 Participants | 7 Participants |
| Diagnosis Pancreatic Cancer | 1 Participants | 1 Participants | 2 Participants |
| Eastern Cooperative Oncology Group (ECOG) Performance Status 0 | 2 Participants | 3 Participants | 5 Participants |
| Eastern Cooperative Oncology Group (ECOG) Performance Status 1 | 1 Participants | 3 Participants | 4 Participants |
| Height | 166.7 centimeter (cm) STANDARD_DEVIATION 2.08 | 164.0 centimeter (cm) STANDARD_DEVIATION 7.64 | 164.9 centimeter (cm) STANDARD_DEVIATION 6.27 |
| Prior Radiation Therapy Did not have prior radiation therapy | 0 Participants | 5 Participants | 5 Participants |
| Prior Radiation Therapy Had prior radiation therapy | 3 Participants | 1 Participants | 4 Participants |
| Prior Surgery/Procedure Did not have surgery/procedure | 2 Participants | 3 Participants | 5 Participants |
| Prior Surgery/Procedure Had prior surgery/procedure | 1 Participants | 3 Participants | 4 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 3 Participants | 6 Participants | 9 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) White | 0 Participants | 0 Participants | 0 Participants |
| Region of Enrollment Japan | 3 Participants | 6 Participants | 9 Participants |
| Sex: Female, Male Female | 1 Participants | 3 Participants | 4 Participants |
| Sex: Female, Male Male | 2 Participants | 3 Participants | 5 Participants |
| Weight | 65.57 kilogram (kg) STANDARD_DEVIATION 8.976 | 64.23 kilogram (kg) STANDARD_DEVIATION 6.575 | 64.68 kilogram (kg) STANDARD_DEVIATION 6.9 |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 0 / 3 | 0 / 6 |
| other Total, other adverse events | 3 / 3 | 6 / 6 |
| serious Total, serious adverse events | 0 / 3 | 1 / 6 |
Outcome results
Primary
Number of Participants Who Discontinued Study Drug Due to TEAEs
Time frame: From the first dose of the study drug up to 28 days after the last dose of the study drug (up to Cycle 22 Day 49) (Cycle length =21 days)
Population: The safety analysis set included participants who received at least 1 dose of study drug.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Cohort 1: Niraparib 200 mg | Number of Participants Who Discontinued Study Drug Due to TEAEs | 0 Participants |
| Cohort 2: Niraparib 300 mg | Number of Participants Who Discontinued Study Drug Due to TEAEs | 2 Participants |
Primary
Number of Participants With Dose Limiting Toxicities (DLTs)
DLT was evaluated as per National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), v4.03 and defined as any of the following events occurring during Cycle 1 that were considered by investigator to be related with niraparib: Any Grade 5 or 4 hematologic toxicity, except Grade 4 neutropenia less than (\<) 7 days; Grade 3 or 4 neutropenia with fever greater than (\>) 38.5 degree Celsius and/or infection requiring antibiotic/anti-fungal treatment; Any Grade 3, 4,or 5 non-hematologic toxicity except: Grade 3 nausea, vomiting, diarrhea/dehydration occurring in setting of inadequate compliance with supportive care and lasting \<48 hours, Inadequately treated hypersensitivity reactions, Grade 3 acidosis/alkalosis that responded to intervention by improving to less than or equal to (\<=) Grade 2 within 48 hours, Isolated asymptomatic Grade 3 amylase elevation, hypercholesterolemia and hypertriglyceridemia; Any TEAE leading to an interruption of niraparib for \>14 days.
Time frame: Baseline up to Day 21 in Cycle 1 (Cycle length=21 days)
Population: The DLT-evaluable set included participants who had received at least 80 percent (%) of planned doses of niraparib in Cycle 1 (for at least 17 days out of 21 days) unless interrupted by study drug-related toxicities and had sufficient follow-up data considered by sponsor and investigator to determine whether DLT occurred.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Cohort 1: Niraparib 200 mg | Number of Participants With Dose Limiting Toxicities (DLTs) | 0 Participants |
| Cohort 2: Niraparib 300 mg | Number of Participants With Dose Limiting Toxicities (DLTs) | 1 Participants |
Primary
Number of Participants With Grade 3 or Higher TEAEs
TEAEs were graded as per the NCI-CTCAE version 4.03. As per the NCI-CTCAE, Grade 1 (mild, asymptomatic or mild symptoms); Grade 2 (moderate, minimal, local or noninvasive intervention indicated); Grade 3 (severe or medically significant but not immediately life-threatening, hospitalization or prolongation of hospitalization indicated); Grade 4 (life-threatening consequences, urgent intervention indicated); Grade 5 (death related to adverse event \[AE\]).
Time frame: From the first dose of the study drug up to 28 days after the last dose of the study drug (up to Cycle 22 Day 49) (Cycle length =21 days)
Population: The safety analysis set included participants who received at least 1 dose of study drug.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Cohort 1: Niraparib 200 mg | Number of Participants With Grade 3 or Higher TEAEs | 1 Participants |
| Cohort 2: Niraparib 300 mg | Number of Participants With Grade 3 or Higher TEAEs | 6 Participants |
Primary
Number of Participants With Serious TEAEs
Time frame: From the first dose of the study drug up to 28 days after the last dose of the study drug (up to Cycle 22 Day 49) (Cycle length =21 days)
Population: The safety analysis set included participants who received at least 1 dose of study drug.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Cohort 1: Niraparib 200 mg | Number of Participants With Serious TEAEs | 0 Participants |
| Cohort 2: Niraparib 300 mg | Number of Participants With Serious TEAEs | 1 Participants |
Primary
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
Time frame: From the first dose of the study drug up to 28 days after the last dose of the study drug (up to Cycle 22 Day 49) (Cycle length =21 days)
Population: The safety analysis set included participants who received at least 1 dose of study drug.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Cohort 1: Niraparib 200 mg | Number of Participants With Treatment-emergent Adverse Events (TEAEs) | 3 Participants |
| Cohort 2: Niraparib 300 mg | Number of Participants With Treatment-emergent Adverse Events (TEAEs) | 6 Participants |
Secondary
AUC24：Area Under the Plasma Concentration-time Curve From Time 0 to 24 Hours for Niraparib
Time frame: Cycle 1 Days 1 and 21: pre-dose and at multiple time points (up to 24 hours) post-dose (Cycle length =21 days)
Population: The PK analysis set included participants with sufficient dosing and PK data to reliably estimate 1 or more PK parameters. Here number analyzed were participants who were evaluable for the outcome measure at given time points.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|---|
| Cohort 1: Niraparib 200 mg | AUC24：Area Under the Plasma Concentration-time Curve From Time 0 to 24 Hours for Niraparib | Cycle 1 Day 21 | 13040 hour*nanogram per milliliter (h*ng/mL) | Standard Deviation 6493.3 |
| Cohort 1: Niraparib 200 mg | AUC24：Area Under the Plasma Concentration-time Curve From Time 0 to 24 Hours for Niraparib | Cycle 1 Day 1 | 4931 hour*nanogram per milliliter (h*ng/mL) | Standard Deviation 2905 |
| Cohort 2: Niraparib 300 mg | AUC24：Area Under the Plasma Concentration-time Curve From Time 0 to 24 Hours for Niraparib | Cycle 1 Day 1 | 6270 hour*nanogram per milliliter (h*ng/mL) | Standard Deviation 2631.2 |
| Cohort 2: Niraparib 300 mg | AUC24：Area Under the Plasma Concentration-time Curve From Time 0 to 24 Hours for Niraparib | Cycle 1 Day 21 | 19540 hour*nanogram per milliliter (h*ng/mL) | Standard Deviation 3117.2 |
Secondary
Cmax: Maximum Observed Plasma Concentration for Niraparib
Time frame: Cycle 1 Days 1 and 21: pre-dose and at multiple time points (up to 24 hours) post-dose (Cycle length =21 days)
Population: The pharmacokinetic (PK) analysis set included participants with sufficient dosing and PK data to reliably estimate 1 or more PK parameters. Here number analyzed were participants who were evaluable for the outcome measure at given time points.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|---|
| Cohort 1: Niraparib 200 mg | Cmax: Maximum Observed Plasma Concentration for Niraparib | Cycle 1 Day 1 | 442.9 nanogram per milliliter (ng/mL) | Standard Deviation 195.09 |
| Cohort 1: Niraparib 200 mg | Cmax: Maximum Observed Plasma Concentration for Niraparib | Cycle 1 Day 21 | 729.2 nanogram per milliliter (ng/mL) | Standard Deviation 387.5 |
| Cohort 2: Niraparib 300 mg | Cmax: Maximum Observed Plasma Concentration for Niraparib | Cycle 1 Day 1 | 529.6 nanogram per milliliter (ng/mL) | Standard Deviation 149.22 |
| Cohort 2: Niraparib 300 mg | Cmax: Maximum Observed Plasma Concentration for Niraparib | Cycle 1 Day 21 | 1167 nanogram per milliliter (ng/mL) | Standard Deviation 194.94 |
Secondary
Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for Niraparib
Time frame: Cycle 1 Days 1 and 21: pre-dose and at multiple time points (up to 24 hours) post-dose (Cycle length =21 days)
Population: The PK analysis set included participants with sufficient dosing and PK data to reliably estimate 1 or more PK parameters. Here number analyzed were participants who were evaluable for the outcome measure at given time points.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Cohort 1: Niraparib 200 mg | Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for Niraparib | Cycle 1 Day 1 | 4.000 hours |
| Cohort 1: Niraparib 200 mg | Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for Niraparib | Cycle 1 Day 21 | 3.950 hours |
| Cohort 2: Niraparib 300 mg | Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for Niraparib | Cycle 1 Day 1 | 4.035 hours |
| Cohort 2: Niraparib 300 mg | Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for Niraparib | Cycle 1 Day 21 | 2.890 hours |